The mysterious case of Eli Lilly’s obesity drug - Takeaways - MDSpire

The mysterious case of Eli Lilly’s obesity drug

  • By

  • Elaine Chen

  • Allison DeAngelis

  • June 25, 2026

  • 0 min

Share

  • 1

    Eli Lilly's obesity candidate, retatrutide, has been granted access to one individual through the FDA's compassionate use program.

  • 2

    The podcast discusses the increasing trend of mergers and acquisitions in the pharmaceutical industry.

  • 3

    Lilly is exploring investment opportunities in a hair loss drug.

  • 4

    The FDA has recently reversed its stance on drugs for rare diseases.

  • 5

    The episode features insights from Lizzy Lawrence regarding Lilly's drug access and industry trends.

Original Source(s)

The mysterious case of Eli Lilly’s obesity drug

  • by Elaine Chen, Allison DeAngelis

  • June 25, 2026

Related Content

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

Effects of metabolic syndrome on pulmonary infection in pediatric bronchial asthma: a narrative review

Members Spotlighted for Accreditation, Awards, and Research